CEO J. Scott Wolchko assumes CFO role after Edward Dulac's resignation; stock plan expanded

FATE THERAPEUTICS INC

CFO Edward Dulac resigned effective June 14, 2024; CEO J. Scott Wolchko appointed as CFO and principal financial/accounting officer.
Wolchko previously served as CFO from company inception until August 2020; no change to his compensation.
Stockholders approved amendment to 2022 Stock Option Plan, increasing available shares by 8,000,000 to 17,500,000 total.
Other proposals passed: election of three Class II directors, ratification of EY, say-on-pay, officer exculpation amendment.
Broker non-votes were ~6.7M on most items; say-on-pay passed with ~65.4M for vs 25.6M against.

item 5.02 item 5.07 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

J. Scott Wolchko

Chief Financial Officer

FATE · FATE THERAPEUTICS INC

Effective: 2024-06-14
Filed: June 7, 2024, 7:59 PM ET

On June 3, 2024, the board of directors (the “Board”) of Fate Therapeutics, Inc. (the “Company”) appointed J. Scott Wolchko, the Company’s President and Chief Executive Officer, to succeed Edward J. Dulac III as the Company’s Chief Financial Officer and also serve as the Company’s principal financial and accounting officer, effective immediately after Mr. Dulac’s resignation.

Departed

Edward J. Dulac III

Chief Financial Officer

FATE · FATE THERAPEUTICS INC

Effective: 2024-06-14
Successor: J. Scott Wolchko
Filed: June 7, 2024, 7:59 PM ET

Mr. Dulac provided notice of his resignation from his position as the Company’s Chief Financial Officer on May 30, 2024, which resignation shall be effective as of June 14, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

J. Scott Wolchko was appointed as Chief Financial Officer at FATE THERAPEUTICS INC.

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

On June 3, 2024, the board of directors (the “Board”) of Fate Therapeutics, Inc. (the “Company”) appointed J. Scott Wolchko, the Company’s President and Chief Executive Officer, to succeed Edward J. Dulac III as the Company’s Chief Financial Officer and also serve as the Company’s principal financial and accounting officer, effective immediately after Mr. Dulac’s resignation.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Edward J. Dulac III resigned as Chief Financial Officer at FATE THERAPEUTICS INC.

Action: resigned
Role: Chief Financial Officer

Exact text from the filing

Mr. Dulac provided notice of his resignation from his position as the Company’s Chief Financial Officer on May 30, 2024, which resignation shall be effective as of June 14, 2024.

View on SEC.gov

FATE THERAPEUTICS INC filing history →

Source: SEC EDGAR

accession 0001193125-24-157554

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.